Interferon does not slow or halt the progression of chronic hepatitis C and advanced liver disease in patients who haven’t responded to previous attempts to eradicate the disease, a national study in which the Saint Louis University School of Medicine participated has found.
Patients in the trial who were treated with interferon did experience a significant decrease in viral levels and liver inflammation, but the trial unequivocally demonstrated that treatment with long-term pegylated interferon – also called peginterferon – does not prevent the worsening of liver disease in patients who’ve failed prior treatments.
“The results are this study are very clear – long-term therapy with peginterferon for those with chronic hepatitis C is not effective in preventing progression of liver disease for patients who did not respond to an initial course of treatment,” said Adrian Di Bisceglie, M.D., professor of internal medicine at Saint Louis University School of Medicine and chairman of the trial’s steering committee.
“Furthermore, the relatively high rate of liver disease progression – about 30 percent over nearly four years – indicates the potential severity of chronic hepatitis C and emphasizes the importance of the ongoing search for new and more effective treatments,” Di Bisceglie added.
Results of the study were reported by Di Bisceglie at the annual meeting of the American Association for the Study of Liver Disease in Boston this week.
Hepatitis C infects more than 100 million people worldwide and as many as 4 million people in the U.S. It ranks with alcohol abuse as the most common cause of chronic liver disease and leads to some 1,000 liver transplants in the U.S. each year.
The randomized, multi-site study involved 1,050 patients with chronic hepatitis C who’d failed prior treatments to eradicate the infection. All had advanced liver fibrosis – a gradual scarring of the liver that puts patients at risk for progressive liver disease.
The trial assessed whether long-treatment with peginterferon prevented the patients from developing cirrhosis, liver failure or liver cancer. Roughly half of the patients in the study received 90 micrograms of peginterferon in weekly injections for 3.5 years. The other half, the control group, underwent the same follow-up and care as the treated patients, including liver biopsies, quarterly clinic visits and blood tests.
At the end of the study, while patients treated with interferon did have significantly lower blood levels of the hepatitis C virus and less liver inflammation, 34.1 percent of them had experienced one or more of the following outcomes: excess fluid in the abdomen; brain and nervous system damage; cirrhosis (for those who did not have it initially); liver cancer; or death. Of patients in the control group, 33.8 percent experienced one or more of the outcomes.
Among treated patients, adverse side effects had caused 17 percent to stop peginterferon after 18 months and 30 percent to stop treatment by the end of the trial.
Donn Walker | EurekAlert!
Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland
Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy